Replimune Group Shares Are Trading Higher After the Company Announced It Received Breakthrough Therapy Designation Status for RP1 and Will Submit an RP1 Biologics License Application to the FDA Under an Accelerated Approval Pathway.
Replimune Group Shares Are Trading Higher After the Company Announced It Received Breakthrough Therapy Designation Status for RP1 and Will Submit an RP1 Biologics License Application to the FDA Under an Accelerated Approval Pathway.
Replimune集團的股票在公司宣佈已獲得RP1突破性療法資格後上漲，並將向FDA提交RP1生物製品許可申請，採用加速審批程序。
Replimune Group Shares Are Trading Higher After the Company Announced It Received Breakthrough Therapy Designation Status for RP1 and Will Submit an RP1 Biologics License Application to the FDA Under an Accelerated Approval Pathway.
Replimune集團宣佈獲得RP1的突破性療法指定地位，並將通過加速批准途徑向美國食品藥品管理局提交RP1生物製劑許可申請，此後，該公司股價走高。
資訊熱榜
更新時間